Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analyst sentiment is broadly positive: Olema has a “Moderate Buy” consensus, with 11 of 13 analysts rating it a buy; the average 12-month price target is $40.60.
• The shares are near their 12-month low: OLMA opened at $7.33, compared with a 12-month range of $6.24 to $36.26.
• Olema reported quarterly EPS of negative $0.61, missing analysts’ estimate of negative $0.55; analysts forecast full-year EPS of negative $2.43.

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $40.60.

Several research analysts recently commented on OLMA shares. Weiss Ratings raised Olema Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, September 21st. Citigroup lowered their target price on shares of Olema Pharmaceuticals to $59.00 and set a "buy" rating on the stock in a research note on Tuesday, August 11th. Stifel Nicolaus dropped their target price on shares of Olema Pharmaceuticals from $48.00 to $30.00 and set a "buy" rating for the company in a report on Monday, September 14th. HC Wainwright reduced their target price on shares of Olema Pharmaceuticals from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, July 25th.

Institutional Trading of Olema Pharmaceuticals

Several large investors have recently bought and sold shares of OLMA. Janus Henderson Group PLC raised its holdings in Olema Pharmaceuticals by 5.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company's stock valued at $106,013,000 after acquiring an additional 398,294 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth approximately $88,803,000. BlackRock Inc. acquired a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth approximately $84,001,000. Siren L.L.C. boosted its holdings in shares of Olema Pharmaceuticals by 44.1% during the 1st quarter. Siren L.L.C. now owns 4,756,949 shares of the company's stock worth $70,926,000 after purchasing an additional 1,456,249 shares during the last quarter. Finally, Jennison Associates LLC grew its position in shares of Olema Pharmaceuticals by 89.0% in the first quarter. Jennison Associates LLC now owns 1,822,123 shares of the company's stock valued at $27,168,000 after purchasing an additional 858,126 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $7.33 on Friday. The stock has a market capitalization of $641.38 million, a P/E ratio of -3.46 and a beta of 2.12. The business has a 50 day simple moving average of $8.49 and a two-hundred day simple moving average of $13.65. Olema Pharmaceuticals has a 12 month low of $6.24 and a 12 month high of $36.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.86 and a quick ratio of 8.86.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.06). As a group, analysts predict that Olema Pharmaceuticals will post -2.43 EPS for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers, with an emphasis on hormone receptor-positive breast cancer. The company's research is centered on treatments designed to address cancer biology and resistance mechanisms that can limit the effectiveness of existing endocrine therapies.

Olema's lead product candidate is palazestrant, an oral selective estrogen receptor degrader (SERD) being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.